Skip to main navigation
  • About
    • Our Vision
    • Our Approach
    • Our Team
  • Pipeline
    • DARE-BV1
    • OVAPRENE®
    • Sildenafil Cream, 3.6%
  • Partners
  • Consumers
  • Investors
    • Overview
    • Press Releases
    • Presentation, Events & Webcasts
    • Stock Information
      • Stock Quote & Chart
      • Historic Stock Lookup
      • Analyst Coverage
    • Financial Information
      • Financials Overview
      • SEC Filings
      • Annual Reports & Proxies
      • Quarterly Results
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management
    • Contact
  • Careers
  • Contact Us
    Dare Biosciences
    • Investors
    • Press releases
    • Presentations, Events & Webcasts
    • Stock information
    • Financial Information
    • Corporate governance
    • Contact

    Investors

    Investors

    Corporate Profile

    Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.

    AST Shareholder Services:
    www.astfinancial.com/contact-us
    (800) 937-5449

    Stock Information

    Change
    Volume
    52 Week High
    52 Week Low
    Feb 6, 2023 8:20 PM EST

    Data Provided by Refinitiv. Minimum 15 minutes delayed.

    Press Releases

    • Daré Bioscience to Participate in Three February Conferences

      02-01-2023

    • Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms

      01-26-2023

    • Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause

      01-09-2023

    View all press releases »

    Events & Presentations

    • 3rd Annual Women’s Health Innovation Series: Reproductive Health Innovation Summit

      02-15-2023 to 02-16-2023

    • SVB Securities Global Biopharma Conference

      02-13-2023 to 02-16-2023

    View all events & presentations »
    • Request email alerts |
    • Print this page |
    • Search investor site |

    © 2023 by Daré Bioscience | Daré Bioscience® is a registered trademark of Daré Bioscience, Inc.

    Privacy Policy | Terms of Service | COI Policy |

    Scroll to top